Method of presenting oncology treatment outcomes influences patient treatment decision-making in metastatic colorectal cancer

Annals of Surgical Oncology

Volumn 13, Issue 1, 2006, Pages 86-95

  Martin II, Robert C G ^a   McGuffin, Sheri A ^a   Roetzer, Lynne M ^a   Abell, Troy D ^b   Studts, Jamie L ^a  

^a University of Louisville School of Medicine   (United States)

^b Abell Research Consulting   (United States)

Author keywords

Chemotherapy; Decision analysis; Metastatic colorectal cancer; Surgery

Indexed keywords

ADULT; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DECISION MAKING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PHYSICIAN-PATIENT RELATIONS; STUDENTS, MEDICAL;

EID: 30944447669     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.03.086     Document Type: Review

References (39)

1. Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology 2003; 125:1645-50.
2. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-46.
3. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr 1999; 25:44-51.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
5. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35:1338-42.
6. Engstrom PF, Saltz LB. Update: colorectal cancer guidelines. J Natl Compr Cancer Network 2003; 1:9-16.
7. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000; 135: 657-62.
8. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7:643-50.
9. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18.
10. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors, nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 1995; 31A:1955-9.
11. Bremnes RM. Experience with and attitudes to chemotherapy among newly employed nurses in oncological and surgical departments: a longitudinal study. Support Care Cancer 1999; 7:11-6.
12. Jansen SJ, Kievit J, Nooij MA, Stiggelbout AM. Stability of patients' preferences for chemotherapy: the impact of experience. Med Decis Making 2001; 21:295-306.
13. Jansen SJ, Kievit J, Nooij MA, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 2001; 84:1577-85.
14. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995; 13:858-68.
15. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300:1458-60.
16. Piga A, Graziano F, Zahra G, Cellerino R. Attitudes of non-oncology physicians dealing with cancer patients. A survey based on clinical scenarios in Ancona province, central Italy. Tumori 1996; 82:423-9.
17. Elger BS, Harding TW. Should cancer patients be informed about their diagnosis and prognosis? Future doctors and lawyers differ. J Med Ethics 2002; 28:258-65.
18. Rodriguez-Marin J, Lopez-Roig S, Pastor MA. Doctors' decision-making on giving information to cancer patients. Psychol Health 1996; 11:839-44.
19. Chao C, Studts JL, Abell T, et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003; 21:4299-305.
20. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8.
21. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-62.
22. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995; 82:1397-400.
23. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
24. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13-29.
25. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995; 82:1397-400.
26. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8.
27. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-62.
28. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13-29.
29. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
30. Flesch R. A new readability yardstick. J Appl Psychol 1948; 32:221-33.
31. Sonpavde G. Communicating the value of adjuvant chemotherapy. J Clin Oncol 2003; 21:948-9.
32. Weinfurt KP, Depuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in phase I clinical trials. Cancer 2005; 103:140-7.
33. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35:1338-42.
34. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
35. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-505.
36. Fong Y, Blumgart LH, Cohen A, Fortner J, Brennan MF. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220:657-62.
37. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863-71.
38. Nordlinger B, Rougier P. Liver metastases from colorectal cancer: the turning point. J Clin Oncol 2002; 20:1442-5.
39. Chao C, Studts JL, Abell T, et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003; 21:4299-305.